SEC Form 4 · accession 0001209191-17-046933
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael F. Pehl
Officer — See remarks
Period of report
Jul 28, 2017
Accepted (ET)
Aug 1, 2017 · 4:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 28, 2017 | M | 2,500 | $0.00 | A | 3,488 | D | |
| Common StockF2 | Jul 28, 2017 | F | 1,125 | $134.10 | D | 2,363 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1 | — | Jul 28, 2017 | M | 2,500 | D | — | — | Common Stock | 2,500 | 0 | D |
| Stock Option (right to buy)F4,F3 | $135.41 | Jul 31, 2017 | A | 9,392 | A | — | Jul 31, 2027 | Common Stock | 9,392 | 9,392 | D |
Explanation of responses
- F1All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock.
- F2This amount reflects shares withheld by the Company for the payment of taxes on the vested shares.
- F3Option is immediately exercisable and will vest in four equal annual installments commencing on July 31, 2018.
- F4The option was issued pursuant to the Company's 2017 Stock Incentive Plan.
Remarks
President, Hematology & Oncology